Celsion Corporation (CLSN)

Oncology Corporate Profile

Stock Performance

1.5200
-0.0100

3 Month Stock History Chart

HQ Location

997 Lenox Drive, Suite 100
Lawrenceville, NJ 8648

Company Description

Celsion is an innovative oncology drug development company focused on developing and commercializing more efficient, effective oncology treatments. Celsion's approach and technology delivers high concentrations of anti-cancer agents directly to the tumor site with a goal of maximizing efficacy while minimizing side-effects common to cancer treatment. Celsion's lone oncology focused product is ThermoDox®, a heat activated liposomal capsule containing doxorubicin in Phase III clinical trials for primary liver cancer. ThermoDox® is also in Phase II development for recurrent chest wall breast cancer. Celsion was founded in 1982.

Website: http://www.celsion.com

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
ThermoDox®doxorubicin enhanced with lysolipid thermally sensitive liposomes (LTSL)Hepatocellular carcinoma (HCC)III
ThermoDox®doxorubicin enhanced with lysolipid thermally sensitive liposomes (LTSL)Breast cancerII
ThermoDox®doxorubicin enhanced with lysolipid thermally sensitive liposomes (LTSL)Colorectal cancerII
GEN-1immunotherapyOvarian cancerI
ThermoDox®doxorubicin enhanced with lysolipid thermally sensitive liposomes (LTSL)Hepatocellular carcinoma (HCC)Preclinical
ThermoDox®doxorubicin enhanced with lysolipid thermally sensitive liposomes (LTSL)Pancreatic cancerPreclinical

View additional information on product candidates here »

Source: http://www.celsion.com

Recent News Headlines

Celsion Corporation Announces Positive DSMB Review of Phase 1b OVATION Study in Ovarian Cancer

9/15/2016 05:02 pm

(Celsion) Sept 15, 2016 - Celsion Corporation today announced that the independent Data Safety Monitoring Board (DSMB) has completed its safety review of data from the first three patient cohorts in the ongoing Phase Ib OVATION Study. Based on the DSMB's recommendation, the study will continue as planned and the Company will proceed with dosing in its fourth and final patient cohort at an escalated dose.

Celsion Announces Presentation of OVATION Study Clinical Trial Design at Upcoming ASCO 2016 Meeting

5/24/2016 04:19 pm

(4-traders) May 24, 2016 - Celsion Corporation, an oncology drug development company, today provided an update on its ongoing OVATION study, a Phase Ib dose escalating clinical trial combining GEN-1, the Company's DNA-based immunotherapy, with the standard of care for the treatment of newly-diagnosed patients with advanced ovarian cancer who will undergo neoadjuvant chemotherapy followed by interval debulking surgery.

Heating Chemotherapy Drugs May Improve Bladder Cancer Treatment – Science Daily

5/18/2016 11:04 am

(Newsblog) May 17, 2016 - Scientists have actually discovered that heating the chemotherapy drug mitomycin-C prior to making use of it for treating bladder cancer might radically enhance its efficacy.

Celsion Corporation Announces Positive Data from the First Cohort of Patients in the OVATION Study

5/2/2016 04:24 pm

(TheStreet) May 2, 2016 - Cession Corporation today announced data from the first cohort of patients in its Phase Ib dose escalating clinical trial (the OVATION Study) combining GEN-1, the Company's DNA-based immunotherapy, with the standard of care for the treatment of newly-diagnosed patients with advanced ovarian cancer who will undergo neoadjuvant chemotherapy followed by interval debulking surgery.

Insurers Probed on Hepatitis C Drug Coverage

3/3/2016 12:00 pm

(Wall Street Journal) Mar 2, 2016 - New York's attorney general is investigating state health-insurance companies for allegedly restricting coverage of drugs that can cure hepatitis C, saying that the firms have inappropriately rationed care by denying patients expensive but effective medication.

NanoString Technologies and Merck Expand Collaboration to Develop and Commercialize Novel Diagnostic Test to Predict Response to KEYTRUDA® (pembrolizumab)

3/1/2016 11:04 am

(NanoString) Feb 29, 2016 - NanoString Technologies, Inc., a provider of life science tools for translational research and molecular diagnostic products, today announced that it has entered into a collaboration agreement with Merck, known as MSD outside the US and Canada, through a subsidiary, to develop and commercialize a novel diagnostic assay to predict response to Keytruda® (pembrolizumab), Merck’s anti-PD-1 therapy.

Trillium Therapeutics Doses First Patient With TTI-621, a Novel Immune Checkpoint Inhibitor Targeting CD47

2/3/2016 11:04 am

(CNNMoney) Feb 3, 2016 - Trillium Therapeutics Inc. a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that it has initiated dosing in its Phase 1 clinical trial of TTI-621 (SIRPaFc), a novel checkpoint inhibitor of the innate immune system, in relapsed or refractory hematologic malignancies.

Opdivo Plus Yervoy Gets FDA OK for Melanoma

1/25/2016 11:01 am

(MedPage Today) Jan 24, 2016 - Indications for the blockbuster cancer drug nivolumab (Opdivo) have expanded again, as the FDA has approved the anti-PD-1 antibody in combination with ipilimumab (Yervoy) for treatment of unresectable or metastatic melanoma.

Celsion Reports Translational Research Data from its Phase 1b Study of GEN-1 Immunotherapy in Recurrent Ovarian Cancer

1/7/2016 05:48 pm

(Celsion) Jan 7, 2016 - Celsion Corporation, today announced new translational data from its Phase 1b study of GEN-1 in patients with platinum-resistant ovarian cancer.

Celsion Receives CFDA Approval to Conduct the OPTIMA Study in China

12/17/2015 05:43 pm

(Celsion) Dec 16, 2015 - Celsion Corporation today announced that it has received Clinical Trial Application (CTA) approval from the China Food and Drug Administration (CFDA) to conduct the ongoing Phase III OPTIMA Study at clinical sites in China.

Celsion Announces Presentation of DIGNITY Phase I/II ThermoDox® Data at the 2015 San Antonio Breast Cancer Symposium

12/14/2015 05:48 pm

(Dotmed.com) Dec 14, 2015 - Celsion Corporation today announced the presentation of results from its ongoing Phase I/II US DIGNITY Study of ThermoDox® in combination with mild hyperthermia in patients with recurrent chest wall (RCW) breast cancer.

Celsion Corporation Enrolls First Patient in the OVATION Study

9/30/2015 04:39 pm

(CNN Money) Sept 30, 2015 - First line, phase 1b trial to assess immunotherapy combining GEN-1 with neo-adjuvant therapies in newly diagnosed ovarian cancer patients.

AstraZeneca Taps Crowd Sourcing To Find Cancer Drug Cocktails

9/22/2015 09:04 am

(Reuters) Sept 22, 2015 - Drugmaker AstraZeneca is harnessing the wisdom of crowds to help mix tomorrow's cancer drug cocktails.

Regorafenib Deemed Not Cost-Effective for Metastatic CRC

9/22/2015 09:03 am

(Physician’s Briefing/HealthDay News) Sept 21, 2015 - Given its high cost, regorafenib provides little added benefit as a third-line treatment for metastatic colorectal cancer, according to a study published online Aug. 24 in the Journal of Clinical Oncology.

Arsenic Trioxide Feasible In Low-, High-Risk Acute Promyelocytic Leukaemia

9/22/2015 09:03 am

(medwireNews) Sept 21, 2015 - The use of arsenic trioxide instead of idarubicin in combination with all-trans retinoic acid (ATRA) is a feasible option in patients with acute promyelocytic leukaemia, regardless of risk level, suggests a phase III trial.

Scientists Identify DNA Alterations as Among Earliest to Occur in Lung Cancer Development

9/22/2015 09:03 am

(Johns Hopkins) Sept 21, 2015 - Working with tissue, blood and DNA from six people with precancerous and cancerous lung lesions, a team of Johns Hopkins scientists has identified what it believes are among the very earliest “premalignant” genetic changes that mark the potential onset of the most common and deadliest form of disease.

Relaxed Guidelines on PSA Testing Might Miss Aggressive Tumors: Study

9/22/2015 09:03 am

(U.S. News & World Report/HealthDay News) Sept 22, 2015 - Relaxed guidelines on prostate cancer screening may delay diagnosis and treatment of aggressive tumors, a new study suggests.

Drug Combination Fights Pancreatic Cancer

9/22/2015 09:03 am

(Stanford Medicine) Sept 21, 2015 - A combination of two drugs, one already approved by the Food and Drug Administration, appears to be effective at shrinking pancreatic cancers in laboratory mice, according to a new study by researchers at the Stanford University School of Medicine.

Takeda to Highlight Ixazomib Clinical Development Program at Upcoming International Myeloma Workshop

9/22/2015 09:03 am

(StreetInsider) Sept 22, 2015 - Takeda Pharmaceutical Company Limited today announced that it will highlight the ixazomib clinical development program during multiple poster sessions at the upcoming 15th International Myeloma Workshop (IMW 2015) to be held in Rome, Italy, from September 23 to 26, 2015.

Cancer Treatment Centers of America at Western Regional Medical Center Launches Next Phase of Immunotherapy Clinical Trial Aimed at Soft-Tissue Cancers

9/22/2015 09:03 am

(CTCA) Sept 17, 2015 - New arm of innovative ‘PembroPlus’ clinical trial targets sarcomas.

ECC 2015 Preview: Scientific Co-chair Peter Naredi, MD, PhD

9/22/2015 09:03 am

(Medscape Medical News) Sept 21, 2015 - ECC 2015 Scientific Co-chair Dr Peter Naredi highlights the major themes of the 2015 European Cancer Congress, including the care of elderly cancer patients and the value of patient advocates.

2015 Symposium Highlights Notable Advances in Breast Cancer Research

9/22/2015 09:03 am

(ASCO) Sept 21, 2015 - Summaries of two notable studies to be presented at the 2015 Breast Cancer Symposium are now available. This will be the final year for the Breast Cancer Symposium, held annually since 2007.

Exclusive: Americans Overpaying Hugely For Cancer Drugs - Academic Study

9/22/2015 09:02 am

(Reuters) Sept 22, 2015 - Americans are paying way over the odds for some modern cancer drugs, with pharmaceutical companies charging up to 600 times what the medicines cost to make, according to an independent academic study. The United States also pays more than double the price charged in Europe for these drugs.

Men and Women Face Cancer Differently

9/22/2015 09:02 am

(Wall Street Journal) Sept 21, 2015 - Women and men with certain types of cancer appear to take very different approaches in deciding how to treat their disease, a new social-media study from Memorial Sloan Kettering found.

Jury Still Out On E-Cigarettes As Cessation Aid, U.S. Doctors Say

9/22/2015 06:05 am

(Reuters Health) Sept 21, 2015 - There isn’t enough evidence yet to say whether e-cigarettes are safe or effective for helping people quit smoking, new U.S. guidelines on tobacco cessation conclude.

Study: Brentuximab Vedotin Effective, Safe in Elderly Hodgkin Lymphoma Patients Who Cannot Tolerate Standard Chemotherapy

9/22/2015 06:05 am

(ASH) Sept 21, 2015 - A study published online in Blood, the Journal of the American Society of Hematology (ASH), reports that bretuximab vedotin is an effective and safe first course of treatment for older Hodgkin lymphoma patients unfit for chemotherapy.

The Utility of Cost Discussions Between Patients With Cancer and Oncologists

9/21/2015 01:00 pm

(AJMC.com) Sept 15, 2015 - Many patients with cancer desire cost discussions with doctors, but those discussions are rare. Nevertheless, cost discussions may lower patient costs—usually without altering treatment.

Celsion and myTomorrows Expand ThermoDox® European Early Access Program to Include Patients with Primary Liver Cancer and Liver Cancer Metastases

8/10/2015 05:01 pm

(StreetInsider) Aug 10, 2015 - Celsion Corporation today announced that it has expanded its Early Access Program (EAP) for lyso-thermosensitive liposomal doxorubicin (LTLD), referred to by Celsion as ThermoDox®, with myTomorrows to include patients with primary liver cancer, also known as hepatocellular carcinoma (HCC) and liver cancer metastases, in all countries of the European Union (EU) territory, Switzerland, Turkey and Israel.

Delcath Gets FDA Orphan Drug Status For Melphalan to Treat Cholangiocarcinoma

7/21/2015 11:05 am

(Pharmaceutical Business Review) July 21, 2015 - US-based Delcath Systems has received orphan drug designation from the US Food and Drug Administration's (FDA) Office of Orphan Products Development (OOPD) for melphalan to treat cholangiocarcinoma.

Celsion Announces Continuing Positive Data from Its Phase 2 DIGNITY Study in Breast Cancer

7/6/2015 04:26 pm

(StreetInsider) July 6, 2015 - Thermodox® demonstrates impressive clinical response rates in this highly refractory form of breast cancer.

Celsion Expands Clinical Development Plan for GEN-1 IL-12 Immunotherapy Program in Ovarian Cancer

4/29/2015 04:56 pm

(Celsion) Apr 29, 2015 - Celsion Corporation announced today an update on its clinical development plans for GEN-1, the Company's DNA-based immunotherapy for the localized treatment of cancer, in ovarian cancer.

Immunovaccine Initiates Phase 2 Clinical Trial of DPX-Survivac Immunotherapy in Recurrent Lymphoma

3/24/2015 12:00 pm

(MarketWatch) Mar 24, 2015 - Trial to test efficacy in Diffuse Large B cell Lymphoma patients with measurable disease.

AACR Supports and Promotes New Documentary on Cancer and Cancer Research

3/11/2015 12:03 pm

(AACR) Mar 10, 2015 - Forty-one members of the American Association for Cancer Research (AACR), including 17 fellows of the AACR Academy, are featured in the upcoming documentary CANCER: THE EMPEROR OF ALL MALADIES.

Novel Approach Helps Prevent Early Menopause in Breast Cancer Patients, Study Finds

3/4/2015 12:00 am

(Loyola Medicine) Mar 4, 2015 - Early menopause can be prevented and fertility may be preserved in young women with early stage breast cancer, according to a study published today in The New England Journal of Medicine.

Celsion Corporation Presents Clinical and Preclinical Data For GEN-1 IL-12 Immunotherapy in Ovarian Cancer at the Molecular Medicine TRI-Conference

2/20/2015 05:01 pm

(Yahoo! Finance) Feb 20, 2015 - Celsion Corporation, a fully-integrated oncology company focused on the development of a high potential portfolio of innovative cancer treatments, today presented clinical and preclinical data demonstrating the safety, biological activity and clinical benefits of GEN-1, its DNA-based immunotherapy, as a single agent in advanced platinum-resistant and recurrent ovarian cancer patients, at the Molecular Medicine TRI-Conference in San Francisco.

Celsion Corporation and myTomorrows Partner to Introduce ThermoDox® Early Access Program in Europe for Patients with Recurrent Chest Wall Breast Cancer

1/21/2015 05:57 pm

(WLOX.com) Jan 20, 2015 - Celsion Corp. today announced that it has signed a license and distribution agreement with myTomorrows to implement an Early Access Program for ThermoDox®, its proprietary heat-activated liposomal encapsulation of doxorubicin, in the European Union (EU) territory plus Switzerland for the treatment of patients with recurrent chest wall (RCW) breast cancer.

Celsion Submits DNA-based Immunotherapy Clinical Protocol to the FDA as Part of a First Line Treatment for Ovarian Cancer

1/7/2015 05:50 pm

(Celsion) Jan 6, 2015 - Lead immunotherapy product candidate GEN-1 to enter dose escalating clinical study in the second half of 2015.

Threshold Pharmaceuticals Announces Phase 1/2 Interim Data Signaling Activity of TH-302 Plus Bevacizumab (Avastin(R)) in Patients With Glioblastoma

11/17/2014 05:01 am

(MarketWatch) Nov 17, 2014 - 64% of patients achieved stable disease or tumor shrinkage on combination therapy following progression on single-agent bevacizumab; U.S. FDA set to fund phase 2 investigator-sponsored trial.